Raymond James & Associates Cor Medix Inc. Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Cor Medix Inc. stock. As of the latest transaction made, Raymond James & Associates holds 47,837 shares of CRMD stock, worth $542,471. This represents 0.0% of its overall portfolio holdings.
Number of Shares
47,837
Previous 49,832
4.0%
Holding current value
$542,471
Previous $215,000
79.53%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding CRMD
# of Institutions
204Shares Held
41.2MCall Options Held
1.33MPut Options Held
1.3M-
Vanguard Group Inc Valley Forge, PA3.98MShares$45.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$40.3 Million0.0% of portfolio
-
Marshall Wace, LLP London, X03.47MShares$39.4 Million0.05% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.32MShares$37.7 Million0.74% of portfolio
-
State Street Corp Boston, MA1.84MShares$20.8 Million0.0% of portfolio
About CorMedix Inc.
- Ticker CRMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,208,200
- Market Cap $467M
- Description
- CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of cathet...